Commentary|Podcasts|August 12, 2025
A New Joint Scientific Statement and What to Watch for at the European Society of Cardiology Congress 2025
Host Craig Beavers reviews key studies and insights from the upcoming ESC Congress 2025, focusing on groundbreaking research in cardiology and treatment advancements.
Advertisement
This week, host Craig Beavers tackles the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 through September 1, 2025. Key data to keep an eye on will include the following:
- The VICTORION-Difference study of inclisiran in hyperlipidemia
- The Essence study of olezarsen in hypertriglyceridemia
- Multiple studies on early discontinuation of aspirin after percutaneous coronary intervention in high-risk acute coronary syndromes
- The DAPT-SHOCK-AMI trial of cangrelor in patients with cardiogenic shock related to acute myocardial infarction
- The ALONE-AF trial about stopping anticoagulation after successful atrial fibrillation ablation
- The ODYSSEY-HCM and MAPLE-HCM studies on mavacamten and aficamten in hypertrophic cardiomyopathy
Stay tuned for upcoming episodes for deeper dives into these data and other key takeaways from ESC.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5